21:45 , Apr 26, 2018 |  BC Extra  |  Company News

Shire reports first sales after neuroscience, rare disease split

In its 1Q18 earnings, Shire plc (LSE:SHP; NASDAQ:SHPG) released its first figures since splitting its neuroscience and rare disease businesses into two divisions (see BioCentury Extra, Jan. 9). For the quarter, Shire's rare disease division generated...
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global biopharma...
21:12 , Jan 5, 2018 |  BC Week In Review  |  Company News

Allergan cutting jobs ahead of Restasis competition

Allergan plc (NYSE:AGN) announced details Thursday of a plan to reduce costs as it braces for potential generic competition to its blockbuster dry eye drug Restasis cyclosporine this year. The company will cut over 1,000...
23:00 , Jan 4, 2018 |  BC Extra  |  Company News

Allergan cutting jobs ahead of Restasis competition

Allergan plc (NYSE:AGN) announced details Thursday of a plan to reduce costs as it braces for potential generic competition to its blockbuster dry eye drug Restasis cyclosporine this year. The company will cut over 1,000...
20:51 , Jun 16, 2017 |  BC Week In Review  |  Company News

GeneriCo wins IPR for Apriso

In a May inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board (PTAB) invalidated all claims in U.S. Patent 8,865,688 covering ulcerative colitis (UC) drug Apriso granulated mesalamine from Valeant Pharmaceuticals International...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

Cosmo, Shire autoimmune news

The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO) upheld the validity of the only Orange Book-listed patent for ulcerative colitis drug Lialda mesalamine from Shire. PTAB evaluated an...
07:00 , Oct 6, 2016 |  BC Extra  |  Company News

PTAB upholds Lialda patent's validity

The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office upheld the validity of the only Orange Book-listed patent for ulcerative colitis drug Lialda mesalamine from Shire plc (LSE:SHP; NASDAQ:SHPG). PTAB evaluated...
07:00 , Apr 25, 2016 |  BioCentury  |  Politics, Policy & Law

SCOTUS to the rescue?

The U.S. Supreme Court will hear arguments on Monday in a case that could either overturn or reinforce policies that unfairly tilt the inter partes review system against patent holders, according to life sciences companies. ...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Company News

Allergan, Shire autoimmune news

The U.S. District Court for the District of Southern Florida upheld a patent protecting Shire’s ulcerative colitis drug Lialda mesalamine and granted an injunction blocking approval and sale of a generic form of the...
01:31 , Mar 30, 2016 |  BC Extra  |  Company News

District court again sides with Shire in Lialda dispute

The U.S. District Court of Southern Florida upheld a patent protecting ulcerative colitis drug Lialda mesalamine from Shire plc (LSE:SHP; NASDAQ:SHPG) and granted an injunction blocking approval and sale of a generic form of the...